Determinants of newly detected human papillomavirus infection in HIV-infected and HIV-uninfected injection drug using women

Sexually Transmitted Diseases

Volumn 36, Issue 3, 2009, Pages 149-156

  Phelan, Darcy F ^a   Gange, Stephen J ^a   Ahdieh Grant, Linda ^b   Mehta, Shruti H ^a   Kirk, Gregory D ^a   Shah, Keerti ^a   Gravitt, Patti ^a  

^a JOHNS HOPKINS BLOOMBERG SCHOOL OF PUBLIC HEALTH   (United States)

^b CENTERS FOR DISEASE CONTROL AND PREVENTION   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ANTIRETROVIRUS AGENT; CANNABIS; COCAINE; DIAMORPHINE; ORAL CONTRACEPTIVE AGENT; PROTEINASE INHIBITOR; RNA DIRECTED DNA POLYMERASE INHIBITOR;

ADULT; ARTICLE; CANNABIS ADDICTION; CD4 LYMPHOCYTE COUNT; CIGARETTE SMOKING; COCAINE DEPENDENCE; CONTROLLED STUDY; DISEASE COURSE; FEMALE; HEROIN DEPENDENCE; HIGH RISK POPULATION; HIGHLY ACTIVE ANTIRETROVIRAL THERAPY; HUMAN; HUMAN IMMUNODEFICIENCY VIRUS INFECTED PATIENT; HUMAN IMMUNODEFICIENCY VIRUS INFECTION; INFECTION RISK; INTRAVENOUS DRUG ABUSE; MAJOR CLINICAL STUDY; NONHUMAN; ORAL CONTRACEPTION; POLYMERASE CHAIN REACTION; SEXUAL BEHAVIOR; SEXUALLY TRANSMITTED DISEASE; UTERINE CERVIX CANCER; VIRUS DETECTION; VIRUS INFECTION; WART VIRUS;

ADULT; BALTIMORE; CANNABIS; COHORT STUDIES; CRACK COCAINE; FEMALE; HIV INFECTIONS; HIV-1; HUMANS; MIDDLE AGED; PAPILLOMAVIRIDAE; PAPILLOMAVIRUS INFECTIONS; PROSPECTIVE STUDIES; RISK FACTORS; RISK-TAKING; SEXUAL BEHAVIOR; SUBSTANCE ABUSE, INTRAVENOUS; TUMOR VIRUS INFECTIONS;

EID: 62849093341     PISSN: 01485717     EISSN: None     Source Type: Journal    
DOI: 10.1097/OLQ.0b013e31818d3df3     Document Type: Article

References (31)

1. Dunne EF, Unger ER, Sternberg M, et al. Prevalence of HPV infection among females in the United States. JAMA 2007; 297:813-819.
2. Chesson HW, Blandford JM, Gift TL, et al. The estimated direct medical cost of sexually transmitted diseases among American youth, 2000. Perspect Sex Reprod Health 2004; 36:11-19.
3. Burchell AN, Winer RL, de Sanjose S, et al. Chapter 6: Epidemiology and transmission dynamics of genital HPV infection. Vaccine 2006; 24(suppl 3):S52-S61.
4. Baseman JG, Koutsky LA. The epidemiology of human papillomavirus infections. J Clin Virol 2005; 32(suppl 1):S16-S24.
5. Plitt SS, Sherman SG, Strathdee SA, et al. Herpes simplex virus 2 and syphilis among young drug users in Baltimore, Maryland. Sex Transm Infect 2005; 81:248-253.
6. Dev D, Lo Y, Ho GY, et al. Incidence of and risk factors for genital human papillomavirus infection in women drug users. J Acquir Immune Defic Syndr 2006; 41:527-529.
7. Palefsky JM, Minkoff H, Kalish LA, et al. Cervicovaginal human papillomavirus infection in human immunodeficiency virus-1 (HIV)-positive and high-risk HIV-negative women. J Natl Cancer Inst 1999; 91:226-236.
8. Vlahov D, Anthony JC, Munoz A, et al. The ALIVE study, a longitudinal study of HIV-1 infection in intravenous drug users: Description of methods and characteristics of participants. NIDA Res Monogr 1991; 109:75-100.
9. Vlahov D, Munoz A, Anthony JC, et al. Association of drug injection patterns with antibody to human immunodeficiency virus type 1 among intravenous drug users in Baltimore, Maryland. Am J Epidemiol 1990; 132:847-856.
10. Ahdieh L. Associations between cervical neoplasia, persistence of HPV infection, HIV infection, and HIV-related immunosuppression in a cohort of injection drug users [dissertation]. Johns Hopkins University, School of Hygiene and Public Health; 1998.
11. Ahdieh L, Munoz A, Vlahov D, et al. Cervical neoplasia and repeated positivity of human papillomavirus infection in human immunodeficiency virus-seropositive and -seronegative women. Am J Epidemiol 2000; 151:1148-1157.
12. Shah KV, Solomon L, Daniel R, et al. Comparison of PCR and hybrid capture methods for detection of human papillomavirus in injection drug-using women at high risk of human immunodeficiency virus infection. J Clin Microbiol 1997; 35:517-519.
13. Diggle P. Analysis of longitudinal data, 2nd ed. Oxford; NY: Oxford University Press, 2002.
14. Vittinghoff E. Regression methods in biostatistics: Linear, logistic, survival, and repeated measures models. New York: Springer, 2005. 15. Palefsky J. Biology of HPV in HIV infection. Adv Dent Res 2006; 19:99-105.
15. Palefsky J. Human papillomavirus infection in HIV-infected persons. Top HIV Med 2007; 15:130-133.
16. Hagensee ME, Cameron JE, Leigh JE, et al. Human papillomavirus infection and disease in HIV-infected individuals. Am J Med Sci 2004; 328:57-63.
17. Ahdieh L, Klein RS, Burk R, et al. Prevalence, incidence, and type-specific persistence of human papillomavirus in human immunodeficiency virus (HIV)-positive and HIV-negative women. J Infect Dis 2001; 184:682-690.
18. de Sanjose S, Almirall R, Lloveras B, et al. Cervical human papillomavirus infection in the female population in Barcelona, Spain. Sex Transm Dis 2003; 30:788-793.
19. Moscicki AB, Palefsky J, Gonzales J, et al. Human papillomavirus infection in sexually active adolescent females: Prevalence and risk factors. Pediatr Res 1990; 28:507-513.
20. Booth RE, Kwiatkowski CF, Chitwood DD. Sex related HIV risk behaviors: Differential risks among injection drug users, crack smokers, and injection drug users who smoke crack. Drug Alcohol Depend 2000; 58:219-226.
21. Minkoff H, Zhong Y, Strickler HD, et al. The relationship between cocaine use and human papillomavirus infections in HIV-seropositive and HIV-seronegative women. Infect Dis Obstet Gynecol 2008; 2008:587082.
22. Minkoff H, Feldman JG, Strickler HD, et al. Relationship between smoking and human papillomavirus infections in HIV-infected and -uninfected women. J Infect Dis 2004; 189:1821-1828.
23. Friedman H, Newton C, Klein TW. Microbial infections, immunomodulation, and drugs of abuse. Clin Microbiol Rev 2003; 16:209-219.
24. Strickler HD, Burk RD, Fazzari M, et al. Natural history and possible reactivation of human papillomavirus in human immunodeficiency virus-positive women. J Natl Cancer Inst 2005; 97:577-586.
25. Grulich AE, van Leeuwen MT, Falster MO, et al. Incidence of cancers in people with HIV/AIDS compared with immunosuppressed transplant recipients: A meta-analysis. Lancet 2007; 370:59-67.
26. Hernandez-Giron C, Smith JS, Lorincz A, et al. High-risk human papillomavirus detection and related risk factors among pregnant and nonpregnant women in Mexico. Sex Transm Dis 2005; 32:613-618.
27. Abramson AL, Nouri M, Mullooly V, et al. Latent human papillomavirus infection is comparable in the larynx and trachea. J Med Virol 2004; 72:473-477.
28. Amelia CA, Lofgren LA, Ronn AM, et al. Latent infection induced with cottontail rabbit papillomavirus. A model for human papillomavirus latency. Am J Pathol 1994; 144:1167-1171.
29. Goldie SJ, Kohli M, Grima D, et al. Projected clinical benefits and cost-effectiveness of a human papillomavirus 16/18 vaccine. J Natl Cancer Inst 2004; 96:604-615.
30. Nelson KE, Galai N, Safaeian M, et al. Temporal trends in the incidence of human immunodeficiency virus infection and risk behavior among injection drug users in Baltimore, Maryland, 1988-1998. Am J Epidemiol 2002; 156:641-653.
31. Armstrong GL. Injection drug users in the United States, 1979-2002: An aging population. Arch Intern Med 2007; 167:166-173.